P3 Health Partners financials
$6.54−5.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.46B | $1.50B | $1.27B | $1.05B | $637.4M |
| Gross profit | -$60.2M | -$58.9M | $1.27B | $1.05B | $637.4M |
| Gross margin | −4.1% | −3.9% | 100.0% | 100.0% | 100.0% |
| Operating income | -$270.3M | -$320.7M | -$167.9M | -$1.56B | -$187.9M |
| Net income | -$147.9M | -$135.8M | -$57.8M | -$270.1M | -$156.5M |
| Net margin | −10.1% | −9.1% | −4.6% | −25.7% | −24.6% |
| Diluted EPS | $-45.26 | $-54.06 | $-31.50 | $-325.00 | $-188.17 |
| EBITDA | -$186.1M | -$226.5M | -$81.3M | -$158.7M | -$179.2M |
| Operating cash flow | -$91.2M | -$110.1M | -$76.0M | -$126.0M | -$66.5M |
| Free cash flow | -$91.3M | -$110.1M | -$77.9M | -$128.3M | -$69.9M |
| Diluted shares | 3.3M | 2.9M | 5.9M | 0.8M | 0.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $25.0M | $38.8M | $36.3M | $17.5M | $140.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $273.4M | $186.4M | $132.0M | $108.5M | $92.4M |
| Total assets | $656.6M | $783.4M | $861.0M | $876.6M | $2.36B |
| Total liabilities | $796.9M | $633.9M | $427.3M | $353.9M | $299.9M |
| Shareholders' equity | -$155.2M | $75.9M | $142.1M | $5.9M | $273.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology